Fox Run Management’s Beam Therapeutics BEAM Stock Holding History

Fox Run Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$586K	Buy	+17,072	New	+$515K	0.1%	408
2025 Q4	–	Sell	-24,476	Closed	-$594K	–	919
2025 Q3	$594K	Buy	24,476 +8,701	+55%	+$173K	0.09%	420
2025 Q2	$268K	Buy	+15,775	New	+$275K	0.04%	671
2023 Q2	–	Sell	-9,839	Closed	-$301K	–	693
2023 Q1	$301K	Buy	+9,839	New	+$388K	0.1%	401

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Fox Run Management's BEAM Position: Q2 2026 in Review

Fox Run Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 17,072 shares worth $586K. The stake represents 0.1% of the portfolio and ranks #408 among its holdings. This is a return to the name: Fox Run Management previously reported a position in BEAM as recently as Q3 2025.

Fox Run Management first reported a position in BEAM in Q1 2023 and has held it in 4 quarters since. The position peaked at $594K in Q3 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Fox Run Management held 17,072 shares of Beam Therapeutics worth $586K as of Q2 2026.
Beam Therapeutics was a new Fox Run Management position in Q2 2026.
Beam Therapeutics made up 0.1% of Fox Run Management's portfolio in Q2 2026, its #408 holding.
Fox Run Management first reported a position in Beam Therapeutics in Q1 2023 and has held it in 4 quarters since.
Fox Run Management's Beam Therapeutics position peaked at $594K in Q3 2025.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.